Your browser doesn't support javascript.
loading
Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.
Jiang, Haiping; Yu, Xiongfei; Li, Ning; Kong, Mei; Ma, Zhimin; Zhou, Donghui; Wang, Weibin; Wang, Haohao; Wang, Haiyong; He, Kuifeng; Li, Zhongqi; Lu, Yimin; Zhang, Jing; Zhao, Kui; Zhang, Yafei; Xu, Nong; Li, Ziran; Liu, Ying; Wang, Yan; Wang, Yisen; Teng, Lisong.
Affiliation
  • Jiang H; Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Yu X; Department of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Li N; Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Kong M; Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Ma Z; Department of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Zhou D; Department of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Wang W; Department of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Wang H; Department of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Wang H; Department of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • He K; Department of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Li Z; Department of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Lu Y; Department of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Zhang J; Department of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Zhao K; Department of Nuclear Medicine, PET Centre, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Zhang Y; Department of Nuclear Medicine, PET Centre, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Xu N; Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Li Z; Department of Medical Science and Strategy Oncology, Innovent Biologics, Inc, Suzhou, China.
  • Liu Y; Department of Medical Science and Strategy Oncology, Innovent Biologics, Inc, Suzhou, China.
  • Wang Y; Department of Medical Science and Strategy Oncology, Innovent Biologics, Inc, Suzhou, China.
  • Wang Y; Department of Translational Medicine, Innovent Biologics, Inc, Suzhou, China.
  • Teng L; Department of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China lsteng@zju.edu.cn.
J Immunother Cancer ; 10(3)2022 03.
Article in En | MEDLINE | ID: mdl-35296556
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adenocarcinoma / Neoadjuvant Therapy Type of study: Prognostic_studies Limits: Humans Language: En Journal: J Immunother Cancer Year: 2022 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adenocarcinoma / Neoadjuvant Therapy Type of study: Prognostic_studies Limits: Humans Language: En Journal: J Immunother Cancer Year: 2022 Document type: Article Affiliation country: Country of publication: